Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
5
×
clinical trials
life sciences
national blog main
alnylam pharmaceuticals
fda
rna interference
patisiran
alexion pharmaceuticals
aminolevulinic acid
biotech
deals
drugs
givosiran
hereditary transthyretin amyloidosis
national top stories
onpattro
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
complement system
craig mello
dicerna pharamceuticals
generalized myasthenia gravis
hepatitis b
hepatitis b virus
immune-mediated necrotizing myopathy
inotersen
john maraganore
new york blog main
new york top stories
nobel prize
What
drug
5
×
pharmaceuticals
5
×
alnylam
medicine
rnai
disease
fda
interference
medicines
ok
pharma
rna
second
seek
speedy
afternoon
ago
alnylam’s
alternative
approval
approved
autoimmune
candidate
caught
causing
cleared
data
deal
dicerna
expensive
eye
far
gene
gets
hepatitis
history
indicated
intended
landmark
lead
Language
unset
Current search:
pharmaceuticals
×
drug
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug